ACCEL Hypochondroplasia Trials | Hypochondroplasia Research
广告ACCEL is a clinical program evaluating infigratinib in hypochondroplasia. Review progra…No treatment given · Ages 2.5 to 17 years · No treatment in PROPEL
No treatment given · Ages 2.5 to 17 years · No treatment in PROPEL
反馈